Genmab Historical Cash Flow
| GMAB Stock | USD 21.83 0.28 1.27% |
Analysis of Genmab AS cash flow over time is an excellent tool to project Genmab AS future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Change In Working Capital of 1.4 B or Begin Period Cash Flow of 10.4 B as it is a great indicator of Genmab AS ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Genmab AS latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Genmab AS is a good buy for the upcoming year.
Genmab |
About Genmab Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Genmab balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Genmab's non-liquid assets can be easily converted into cash.
Genmab AS Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Genmab AS to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Genmab AS operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Genmab AS's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Genmab AS current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.At present, Genmab AS's Change In Cash is projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow is expected to grow to about 7.4 B, whereas Other Cashflows From Financing Activities is forecasted to decline to about 46.5 M.
Genmab AS cash flow statement Correlations
Click cells to compare fundamentals
Genmab AS Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Genmab AS cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 3.0B | 3.7B | 1.7B | 936M | 5.0B | 5.2B | |
| Free Cash Flow | 1.2B | 6.1B | 2.0B | 3.6B | 7.0B | 7.4B | |
| Change In Working Capital | (1.2B) | 987M | (770M) | (1.9B) | 1.4B | 1.4B | |
| Begin Period Cash Flow | 533M | 3.6B | 7.3B | 9.0B | 9.9B | 10.4B | |
| Other Cashflows From Financing Activities | 3.7B | 115M | 85M | 192M | 49M | 46.6M | |
| Depreciation | 139M | 259M | 248M | 362M | 295M | 309.8M | |
| Other Non Cash Items | (216M) | 409M | (997M) | (2.0B) | (622M) | (590.9M) | |
| Capital Expenditures | 111M | 307M | 252M | 317M | 376M | 394.8M | |
| Total Cash From Operating Activities | 1.3B | 6.4B | 2.2B | 3.9B | 7.4B | 7.7B | |
| Net Income | 2.9B | 5.9B | 4.0B | 7.0B | 5.6B | 5.9B | |
| Total Cash From Financing Activities | 3.7B | 71M | (420M) | (789M) | (606M) | (575.7M) | |
| End Period Cash Flow | 3.6B | 7.3B | 9.0B | 9.9B | 14.9B | 15.6B | |
| Stock Based Compensation | 147M | 200M | 310M | 439M | 586M | 615.3M | |
| Sale Purchase Of Stock | (9M) | (25M) | (447M) | (908M) | (564M) | (535.8M) | |
| Investments | (2.0B) | (2.4B) | (709M) | (2.8B) | (976M) | (1.0B) | |
| Total Cashflows From Investing Activities | (2.0B) | (2.4B) | (961M) | (2.8B) | (2.5B) | (2.4B) | |
| Dividends Paid | 9M | 115M | 135M | 280M | 322M | 338.1M | |
| Change To Account Receivables | (1.7B) | 306M | (1.1B) | (2.1B) | 797M | 836.9M | |
| Change To Netincome | 211M | 422M | (314M) | (78M) | (70.2M) | (66.7M) | |
| Change To Liabilities | 440M | 681M | 304M | 283M | 325.5M | 240.1M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.You can also try the Stocks Directory module to find actively traded stocks across global markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.38) | Earnings Share 1.02 | Revenue Per Share 30.6997 | Quarterly Revenue Growth 0.176 | Return On Assets 0.1095 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genmab AS's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.